A Phase 1, Non-Randomized, Open Label Study to Determine the Effect of Rifampin on the Pharmacokinetics of a Single Oral Dose of 160 mg Regorafenib (BAY73-4506) in Healthy Volunteers

Inclusion Criteria:

- Healthy male subject

- Age: 18 to 45 years (inclusive) at the first screening examination / visit

- Body mass index (BMI): 18 to 32 kg/m² (inclusive)

- Ability to understand and follow study-related instructions

- Subjects enrolled in this study must use adequate barrier birth control measures
prior to, during the course of the study, and 3 months after the last administration
of regorafenib. An adequate contraception includes the use of condoms or a vasectomy.
In addition, adequate birth control measures for the subject's partner is required,
such as a hormonal contraception with implants or combined oral contraceptives,
certain intrauterine devices, bilateral tubal ligation, or hysterectomy.

Exclusion Criteria:

- Clinically significant disease or condition

- Recent serious infection